-
Mashup Score: 9ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results - 7 month(s) ago
Nature Medicine – In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published - The ASCO Post - 7 month(s) ago
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in breast milk and may prove to be a new tool for early diagnosis of breast cancer in the postpartum period. The study was led by Cristina Sa ura, MD, and Ana Vivancos, MD, both of VHIO, and the first results were
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 11Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes - 7 month(s) ago
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in breast milk and may prove to be a new tool for early diagnosis of breast cancer in the postpartum period. The study was led by Cristina Saura, MD, and Ana Vivancos, MD, both of VHIO, and the first results were
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 17Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma - 7 month(s) ago
Hepatocellular Carcinoma (HCC) is the most common primary liver carcinoma, accounting for 75–85% of all cases. For patients with advanced unresectable…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Practice Changing Abstracts in Upper Tract Urothelial Carcinoma, A Review from the 2022 AUA - Firas Petros - 7 month(s) ago
Firas Petros, Urologic Oncologist from the University of Toledo College of Medicine joins Sam Chang in reviewing practice-changing and hypothesis-generating abstracts from the upper tract urothelial carcinoma podium session at the 2022 Annual Meeting of the American Urological Association (AUA). Dr. Petros first highlights two abstracts that involved the use of circulating tumor DNA as a…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 72Early-Stage Breast Cancer Detection in Breast Milk - 8 month(s) ago
AbstractBreast cancer occurring during pregnancy (PrBC) and postpartum (PPBC) is usually diagnosed at more advanced stages compared with other breast cancer, worsening its prognosis. PPBC is particularly aggressive, with increased metastatic risk and mortality. Thus, effective screening methods to detect early PrBC and PPBC are needed. We report for the first time that cell-free tumor DNA (ctDNA) is present in breast milk (BM) collected from patients with breast cancer. Analysis of ctDNA from BM detects tumor variants in 87% of the cases by droplet digital PCR, while variants remain undetected in 92% of matched plasma samples. Retrospective next-generation sequencing analysis in BM ctDNA recapitulates tumor variants, with an overall clinical sensitivity of 71.4% and specificity of 100%. In two cases, ctDNA was detectable in BM collected 18 and 6 months prior to standard diagnosis. Our results open up the potential use of BM as a new source for liquid biopsy for PPBC detection.Significa
Source: aacrjournals.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0ctDNA Is on the Horizon for Large Cell Lymphoma - 8 month(s) ago
Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing - 8 month(s) ago
This review article critically evaluates the rational for the application of circulating tumour DNA (ctDNA) testing in metastatic breast cancer and presents the currently available methods for ctDNA …
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Holly Chitwood, DNP, FNP-C, AGACNP-BC; and Adria Myers, DNP, AOCNP, APRN, recently published an article on the advantages and disadvantages of circulating tumor DNA analyses.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Patients with #ctDNA clearance post PD1 #immunotherapy have better PFS & OS in this prospective study. Liquid biopsies may be used to rapidly & accurately determine clinical response, especially in the metastatic setting. https://t.co/2eVcs3M7EJ https://t.co/fjXX9PYXLa